NDAs 018735/S-056 and 020327/S-010

SUPPLEMENT APPROVAL

Bracco Diagnostics, Inc.
Attention: Melanie Benson, M.S., R.A.C.
Director, US Regulatory Affairs
259 Prospect Plains Road
Monroe Township, NJ 08831

Dear Ms. Benson:

Please refer to your Supplemental New Drug Application (sNDA) dated March 26, 2015, received March 26, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Isovue® (iopamidol) Injection and Isovue-M® (iopamidol) Injection and Isovue® (iopamidol) Injection Pharmacy Bulk Pack and Imaging Bulk Pack.

We also refer to our letter dated February 27, 2015, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for the class of iodinated contrast media (ICM) products. This information pertains to the risk of hypothyroidism in children, especially neonates.

This supplemental new drug application provides for revisions to the labeling for Isovue® (iopamidol) Injection and Isovue-M® (iopamidol) Injection and Isovue® (iopamidol) Injection Pharmacy Bulk Pack and Imaging Bulk Pack consistent with our February 27, 2015 letter.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

Reference ID: 3788300
We note that your March 26, 2015, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

We are waiving the current requirements of 21 CFR 201.56(d)(1) and 201.57(c)(9)(i) through (iii), regarding the content and format of labeling for subsections 8.1 Pregnancy, 8.2 Labor and Delivery, and 8.3 Nursing Mothers of prescribing information. Your approved labeling for subsections 8.1, 8.2, and 8.3 reflects the content and format requirements of the Pregnancy and Lactation Labeling Rule (79 FR 72063, December 4, 2014) which implements on June 30, 2015.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rene’ Tyson, Safety Regulatory Project Manager, at (301) 796-1476.

Sincerely,

{See appended electronic signature page}

Ira Krefting, M.D.
Deputy Director for Safety
Division of Medical Imaging Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

IRA P KREFTING
07/06/2015